- Home
- QSI vs CRMD Comparison
QSI vs CRMD Comparison
Compare QSI & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QSI
- CRMD
- Stock Information
- Founded
- QSI 2013
- CRMD 2006
- Country
- QSI United States
- CRMD United States
- Employees
- QSI N/A
- CRMD 82
- Industry
- QSI Biotechnology: Pharmaceutical Preparations
- CRMD Biotechnology: Pharmaceutical Preparations
- Sector
- QSI Health Care
- CRMD Health Care
- Exchange
- QSI Nasdaq
- CRMD Nasdaq
- Market Cap
- QSI 633.2M
- CRMD 738.4M
- IPO Year
- QSI N/A
- CRMD 2010
- Fundamental
- Price
- QSI $2.24
- CRMD $12.17
- Analyst Decision
- QSI Buy
- CRMD Strong Buy
- Analyst Count
- QSI 2
- CRMD 6
- Target Price
- QSI $3.25
- CRMD $15.67
- AVG Volume (30 Days)
- QSI 60.2M
- CRMD 1.3M
- Earning Date
- QSI 02-27-2025
- CRMD 03-11-2025
- Dividend Yield
- QSI N/A
- CRMD N/A
- EPS Growth
- QSI N/A
- CRMD N/A
- EPS
- QSI N/A
- CRMD N/A
- Revenue
- QSI $2,266,000.00
- CRMD $12,262,234.00
- Revenue This Year
- QSI $193.90
- CRMD N/A
- Revenue Next Year
- QSI $173.18
- CRMD $300.00
- P/E Ratio
- QSI N/A
- CRMD N/A
- Revenue Growth
- QSI 232.26
- CRMD 41184.20
- 52 Week Low
- QSI $0.61
- CRMD $2.89
- 52 Week High
- QSI $5.77
- CRMD $13.85
- Technical
- Relative Strength Index (RSI)
- QSI 49.02
- CRMD 69.19
- Support Level
- QSI $1.85
- CRMD $7.91
- Resistance Level
- QSI $2.68
- CRMD $11.50
- Average True Range (ATR)
- QSI 0.83
- CRMD 0.68
- MACD
- QSI -0.15
- CRMD 0.46
- Stochastic Oscillator
- QSI 9.95
- CRMD 82.64
About QSI Quantum-Si Incorporated
Quantum-Si Inc is focused on revolutionizing the growing field of proteomics. The company's suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable single-molecule next-generation protein sequencing and genomics, and digitize proteomic research in order to advance drug discovery and diagnostics beyond DNA sequencing.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets.